Concomitant multiple sclerosis and ankylosing spondylitis:: a clinical case report

Estere Zeltiņa; Liga Mekša; Anda Kadiša; Guntis Karelis; Daina Pastare; Sandra Svilpe; Elīna Polunosika; Līga Jaunozoliņa

doi:10.24911/ejmcr/173-1642670323

Concomitant multiple sclerosis and ankylosing spondylitis: a clinical case report

Estere Zeltiņa (Coresponding Author), Liga Mekša, Anda Kadiša, Guntis Karelis, Daina Pastare, Sandra Svilpe, Elīna Polunosika, Līga Jaunozoliņa

Rīga Stradiņš University

Research output: Contribution to journal › Article › peer-review

19 Downloads (Pure)

Abstract

Background: The therapy of patients with concomitant multiple sclerosis (MS) and ankylosing spondylitis (AS) is a challenge for
clinicians. Secukinumab is effective in the treatment of MS. In the clinical case, we present, substantial clinical and radiological
remission in the case of both autoimmune diseases was observed.
Case Presentation: A male adult was diagnosed with relapsing-remitting MS. The patient complained of severe thoraco-lumbar
pain. Magnetic resonance imaging (MRI) led to a diagnosis of AS. Considering that nonsteroidal anti-inflammatory drugs were
ineffective and tumor necrosis factor-α blockers are contraindicated in patients with MS, secukinumab was prescribed. MRI 8
months after initiation of therapy provided clinical stability in consideration of the two autoimmune comorbidities.
Conclusion: Secukinumab is an effective therapy for concomitant MS and AS.

Original language	English
Pages (from-to)	95-101
Journal	European Journal of Medical Case Reports (EJMCR)
Volume	6
Issue number	6
DOIs	https://doi.org/10.24911/ejmcr/173-1642670323
Publication status	Published - 2022

Keywords*

Multiple sclerosis
ankylosing spondylitis
secukinumab
autoimmune disease
case report

Field of Science*

3.2 Clinical medicine

Publication Type*

1.3. Anonymously reviewed scientific article published in a journal with an international editorial board and is available in another indexed database

Access to Document

10.24911/ejmcr/173-1642670323Licence: CC BY

Concomitant multiple sclerosisFinal published version, 597 KBLicence: CC BY

Cite this

@article{ba7271158ab94670ad55f6607e175568,

title = "Concomitant multiple sclerosis and ankylosing spondylitis:: a clinical case report",

abstract = "Background: The therapy of patients with concomitant multiple sclerosis (MS) and ankylosing spondylitis (AS) is a challenge forclinicians. Secukinumab is effective in the treatment of MS. In the clinical case, we present, substantial clinical and radiologicalremission in the case of both autoimmune diseases was observed.Case Presentation: A male adult was diagnosed with relapsing-remitting MS. The patient complained of severe thoraco-lumbarpain. Magnetic resonance imaging (MRI) led to a diagnosis of AS. Considering that nonsteroidal anti-inflammatory drugs wereineffective and tumor necrosis factor-α blockers are contraindicated in patients with MS, secukinumab was prescribed. MRI 8months after initiation of therapy provided clinical stability in consideration of the two autoimmune comorbidities.Conclusion: Secukinumab is an effective therapy for concomitant MS and AS.",

keywords = "Multiple sclerosis, ankylosing spondylitis, secukinumab, autoimmune disease, case report",

author = "Estere Zeltiņa and Liga Mek{\v s}a and Anda Kadi{\v s}a and Guntis Karelis and Daina Pastare and Sandra Svilpe and Elīna Polunosika and Līga Jaunozoliņa",

year = "2022",

doi = "10.24911/ejmcr/173-1642670323",

language = "English",

volume = "6",

pages = "95--101",

journal = "European Journal of Medical Case Reports (EJMCR)",

issn = "2520-4998",

number = "6",

}

TY - JOUR

T1 - Concomitant multiple sclerosis and ankylosing spondylitis:

T2 - a clinical case report

AU - Zeltiņa, Estere

AU - Mekša, Liga

AU - Kadiša, Anda

AU - Karelis, Guntis

AU - Pastare, Daina

AU - Svilpe, Sandra

AU - Polunosika, Elīna

AU - Jaunozoliņa, Līga

PY - 2022

Y1 - 2022

N2 - Background: The therapy of patients with concomitant multiple sclerosis (MS) and ankylosing spondylitis (AS) is a challenge forclinicians. Secukinumab is effective in the treatment of MS. In the clinical case, we present, substantial clinical and radiologicalremission in the case of both autoimmune diseases was observed.Case Presentation: A male adult was diagnosed with relapsing-remitting MS. The patient complained of severe thoraco-lumbarpain. Magnetic resonance imaging (MRI) led to a diagnosis of AS. Considering that nonsteroidal anti-inflammatory drugs wereineffective and tumor necrosis factor-α blockers are contraindicated in patients with MS, secukinumab was prescribed. MRI 8months after initiation of therapy provided clinical stability in consideration of the two autoimmune comorbidities.Conclusion: Secukinumab is an effective therapy for concomitant MS and AS.

AB - Background: The therapy of patients with concomitant multiple sclerosis (MS) and ankylosing spondylitis (AS) is a challenge forclinicians. Secukinumab is effective in the treatment of MS. In the clinical case, we present, substantial clinical and radiologicalremission in the case of both autoimmune diseases was observed.Case Presentation: A male adult was diagnosed with relapsing-remitting MS. The patient complained of severe thoraco-lumbarpain. Magnetic resonance imaging (MRI) led to a diagnosis of AS. Considering that nonsteroidal anti-inflammatory drugs wereineffective and tumor necrosis factor-α blockers are contraindicated in patients with MS, secukinumab was prescribed. MRI 8months after initiation of therapy provided clinical stability in consideration of the two autoimmune comorbidities.Conclusion: Secukinumab is an effective therapy for concomitant MS and AS.

KW - Multiple sclerosis

KW - ankylosing spondylitis

KW - secukinumab

KW - autoimmune disease

KW - case report

UR - https://ejmcr.com/current-issue

U2 - 10.24911/ejmcr/173-1642670323

DO - 10.24911/ejmcr/173-1642670323

M3 - Article

SN - 2520-4998

VL - 6

SP - 95

EP - 101

JO - European Journal of Medical Case Reports (EJMCR)

JF - European Journal of Medical Case Reports (EJMCR)

IS - 6

ER -